Products
  • Products
  • Buy offers
  • Encyclopedia
  • Msds lib
  • Synthesis
  • Reach Info
  • Suppliers
Home> Encyclopedia > Hot Product Listed E   > Erythromycin
114-07-8 structure

Erythromycin

Iupac Name:(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
CAS No.:114-07-8
EINECS(EC#): 204-040-1; 245-407-6; 211-396-1
Molecular Weight:733.937
Molecular Formula:C37H67NO13 (isomer)
Names and Identifiers
Synonyms

(-)-erythromycin (3r*,4s*,5s*,6r*,7r*,9r*,11r*,12r*,13s*,14r*)-4-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione (3r*,4s*,5s*,6r*,7r*,9r*,11r*,12r*,13s*,14r*)-4-[(2,6-dideoxy-3-c-methyl-3-o-methyl-.alpha.-l-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3- (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-4-(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-(((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4 (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione 114e078 44496-EP2272846A1 44496-EP2275422A1 44496-EP2292608A1 44496-EP2305644A1 44496-EP2308866A1 44496-EP2311814A1 44496-EP2311828A1 44496-EP2380568A1 63937kv33d a/t/s AB00051981_09 AB00051981_10 abboticin abomacetin AC-12744 AC-12901 AC1L1ZUR acneryne acnesol adecane-2,10-dione (non-preferred name) ai3-50138 ak-mycin akne cordes losung aknederm ery gel aknemycin akne-mycin akne-mycin (tn) aknin austrias BB_NC-1332 BC205124 bdbm50344942 benzamycin benzamycin pak BG00898815 BIDD:GT0017 BPBIO1_000312 BSPBIO_000282 BSPBIO_002480 C01912 c-23475 cas-114-07-8 cc-27517 CCG-38992 ccris 9078 CHEBI:42355 CHEMBL3735423 CHEMBL532 cpd000544946 CS-2168 c-solve-2 D00140 D02YIZ DB00199 del-mycin derimer deripil DIVK1C_000294 DIVK1C_000397 DIVK1C_000702 dotycin Drmysin dsstox_cid_2991 DTXSID4022991 dumotrycin E.E.S E0751 E-3250 e-base e-base (base) ec 204-040-1 e-glades einecs 204-040-1 em-a emgel EMU emu-v emu-ve emuvin emycin e-mycin e-mycin (base) e-mycin, erythrocin endoeritrin erecin Ergel erimycin-t erisone Eritocina eritomicina eritrocina eritromicina eritromicina [inn-spanish] ermycin eros Erthrogran erthromycin ERY Ery Derm eryacne eryacnen ery-b eryc eryc (base) eryc (tn) eryc 125 eryc sprinkles eryc-125 eryc-250 erycen erycette erycin erycinum eryderm erydermer ery-diolan erygel erygel (tn) eryhexal erymax ery-maxin erymed Erypar ERY-PED erysafe ery-sol erytab ery-tab ery-tab (base) erythra-derm erythro erythrocin erythrocin stearate erythroderm erythrogran erythroguent Erythromast erythromast 36 erythromid erythromycin & vrc3375 erythromycin (jp15/usp/inn) erythromycin (jp17/usp/inn) erythromycin (mixture a,b,c) erythromycin [inn:ban:jan] erythromycin a erythromycin a, b + c erythromycin a, t-stat, pantomicina, hsdb 3074, erytab, drg-0279 erythromycin base erythromycin glucoheptonate erythromycin intravenous erythromycin lactate erythromycin ointment erythromycin sodium lauryl sulfate erythromycin stearate erythromycin, antibiotic for culture media use only erythromycin, bioreagent, suitable for cell culture erythromycin, biotechnology performance certified erythromycin, compd. with monododecyl sulfate, sodium salt erythromycin, for microbiological assay, european pharmacopoeia (ep) reference standard erythromycin, meets usp testing specifications erythromycin, n-demethyl-n-(methyl-11c)- erythromycin, potency: >=850 mug per mg erythromycin, tested according to ph.eur. erythromycin-a erythromycine erythromycine [inn-french] erythromycines erythromycinum erythromycinum [inn-latin] erythro-statin erythro-teva erytop erytrociclin e-solve 2 Gallimycin HMS1920M04 HMS2091D05 HMS2095O04 HMS500O16 hsdb 3074 HY-B0220 IDI1_000294 IDI1_000397 IDI1_000702 Ilocap ilocaps Ilosone ilosone (estolate) iloticina ilotycin ilotycin gluceptate ilotycin t.s ilotycin t.s. inderm inderm gel KBIO1_000294 KBIO1_000397 KBIO1_000702 KBIO2_000555 KBIO2_001139 KBIO2_003123 KBIO2_003707 KBIO2_005691 KBIO2_006275 KBIOGR_001175 KBIOSS_000555 KBIOSS_001139 kesso-mycin L-alpha-Egg-phosphatidylcholine latotryd lederpax LMPK04000006 LS-187077 mephamycin mercina mfcd00084654 MLS001066618 MOLPORT-002-507-378 NCGC00094670-01 NCGC00179619-01 NCGC00179619-02 NCGC00179619-03 nci-c55674 NINDS_000294 NINDS_000397 NINDS_000702 n-methylerythromycin a nsc 55929 nsc55929 nsc756759 oftalmolosa cusi eritromicina oftamolets P.C.E. paediathrocin pantoderm pantodrin pantomicina pce (tn) pce dispertab (base) Pediamycin pfizer-e pharyngocin PRESTWICK_205 PRESTWICK3_000151 primacine propiocine proterytrin retcin robimycin romycin r-p mycin SAM002643510 sansac sans-acne SBI-0051368.P003 SC-13736 SCHEMBL2601 skid gel e SMP1_000119 smr000544946 SPBIO_000778 SPBIO_001226 SPECTRUM_000115 SPECTRUM_000659 SPECTRUM1500280 SPECTRUM2_000759 SPECTRUM2_001263 SPECTRUM4_000538 SPECTRUM5_001596 sr-01000799155 SR-01000799155-2 SR-05000001618-1 Statcin Staticin staticin (tn) stiemicyn stiemycin sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin taimoxin-f theramycin z tiloryth tiprocin torlamicina Torlamicna tox21_111311 tox21_111869 tox21_300515 t-stat t-stat (tn) udima ery gel ULGZDMOVFRHVEP-RWJQBGPGSA-N USP wemid Wintrocin wyamycin s Wyamycin-s ZINC85534336 zx-afc000696

Inchi
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
InChkey
ULGZDMOVFRHVEP-RWJQBGPGSA-N
Canonical Smiles
CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O
Isomers Smiles
CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H]
(C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@@H]3[C@H]([C@@
H](C[C@@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
Properties
Appearance
Fluffy colorless powder
Density
1.2
Melting Point
138-140℃
Boiling Point
818.4°Cat760mmHg
Vapour
4.94E-31mmHg at 25°C
Refractive Index
-74 ° (C=2, EtOH)
Flash Point
448.8°C
Alpha
-74.5 o (C=2, ETHANOL)
Solubility
<1 mg/mL at 22 C , >=100 mg/mL at 22 C (in ethanol)
Color/Form
Hydrated crystals from water
Crystals from water
White or slightly yellow crystals or powder
Other physical and chemical properties
PHYSICAL DESCRIPTION: Fluffy colorless powder or fine white powder. (NTP, 1992)
Stability
Stable under normal temperatures and pressures.
HS Code
29415000
Storage temp
0-6°C
Spectral properties
Specific optical rotation: -78 deg at 25 deg C/D (c = 1.99 in ethanol)
UV max absorption (pH 6.3): 280 nm (epsilon = 50)
Alcoholic solution is levorotatory
IR: 2:363G (Aldrich Library of Infrared Spectra, Aldrich Chemical Co, Milwaukee, WI)
MASS: 3886 (National Bureau of Standards EPA-NIH Mass Spectra Data Base, NSRDS-NBS-63)
Safety and Handling
Hazard Codes
Xn
Risk Statements
R42/43
Safety Statements
S24;S37;S45
Safety

Poison by intravenous and intramuscular routes. Moderately toxic by ingestion, intraperitoneal, and subcutaneous routes. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
Hazard Codes:?HarmfulXn,IrritantXi
Risk Statements: 42/43-36/37/38?
R42/43:May cause sensitization by inhalation and skin contact.?
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 45-37-24-36-26?
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)?
S37:Wear suitable gloves.?
S24:Avoid contact with skin.?
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.?
S36:Wear suitable protective clothing.
WGK Germany: 2
RTECS of Erythromycin (CAS NO.114-07-8): KF4375000

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child TDLo oral 10mg/kg/1D-I (10mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Annals of Internal Medicine. Vol. 115, Pg. 69, 1991.
child TDLo oral 250mg/kg (250mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

GASTROINTESTINAL: OTHER CHANGES

BLOOD: CHANGES IN LEUCOCYTE (WBC) COUNT
Pediatrics. Vol. 90, Pg. 624, 1992.
dog LDLo unreported > 100mg/kg (100mg/kg) ? Antibiotics and Chemotherapy Vol. 2, Pg. 281, 1952.
guinea pig LD50 intraperitoneal 413mg/kg (413mg/kg) ? Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 41, Pg. 555, 1952.
hamster LD50 oral 3018mg/kg (3018mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 41, Pg. 555, 1952.
mouse LD50 intramuscular 394mg/kg (394mg/kg) ? Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 44, Pg. 199, 1955.
mouse LD50 intraperitoneal 280mg/kg (280mg/kg) ? Journal of Antibiotics. Vol. 43, Pg. 938, 1990.
mouse LD50 intravenous 426mg/kg (426mg/kg) ? "Index of Antibiotics from Actinomycetes," Umezawa, H. et al., eds., Tokyo, Univ. of Tokyo Press, 1967Vol. -, Pg. 273, 1967.
mouse LD50 oral 2580mg/kg (2580mg/kg) ? Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 31, Pg. 241, 1974.
mouse LD50 subcutaneous 1800mg/kg (1800mg/kg) ? Antibiotics and Chemotherapy Vol. 2, Pg. 281, 1952.
rat LD50 oral 4600mg/kg (4600mg/kg) ? Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 31, Pg. 241, 1974.
rat LDLo subcutaneous 427mg/kg (427mg/kg) ? Compilation of LD50 Values of New Drugs.

Skin, Eye, and Respiratory Irritations
Possible eye, skin, ... and/or respiratory tract irritation.
Cleanup Methods
Wear approved respiratory protection, chemically compatible gloves, and protective clothing. Wipe up spillage or collect spillage using a high-efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriate labeled container for disposal. Wash spill site.
Transport
MAC
Fire Fighting Procedures
As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.
Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and material.
Fire Potential
This material is assumed to be combustible.
Formulations/Preparations
Erythromycin Lactobionate Preparations Route of Administration Dosage Form Strength Brand of Generic Name (Manufacturer) Parenteral For injection, for IV infusion only 500 mg (of erythromycin) Erythromycin Lactobionate-IV (Abbott) Parenteral For injection, for IV infusion only 500 mg (of erythromycin) Erythromycin Lactobionate-IV ADD-Vantage (Abbott) Parenteral For injection, for IV infusion only 500 mg (of erythromycin) Erythromycin Piggyback (Abbott) Parenteral For injection, for IV infusion only 1 g (of erythromycin) Erythromycin Lactobionate-IV (Abbott) Parenteral For injection, for IV infusion only 1 g (of erythromycin) Erythromycin Lactobinate-IV Add-Vantage (Abbott)
Erythromycin Preparations Route of Administration Dosage Form Strength Brand or Generic Name (Manufacturer) Topical Gel 2% Erythromycin Gel (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name) Topical Gel 2% Erygel (Merz) Topical Ointment 2% Akne-Mycin (Healthpoint) Topical Solution 2% Erythromycin Solution (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name) Topical Solution 2% Erythra-Derm (Paddock)
Erythromycin Ethylsuccinate Preparations Route of Adminstration Dosage Form Strength Brand or Generic Name (Manufacturer) Oral For suspension 100 mg (of erythromycin) per 2.5 mL EryPed Drops (Abbott) Oral For suspension 200 mg (of erythromycin) per 5 mL E.E.S. Granules (Abbott) Oral For suspension 200 mg (of erythromycin) per 5 mL EryPed (Abbott) Oral For suspension 400 mg (of erythromycin) per 5 mL EryPed (Abbott) Oral Suspension 200 mg (of erythromycin) per 5 mL E.E.S. Liquid (Abbott) Oral Suspension 200 mg (of erythromycin) per 5 mL Erythromycin Ethylsuccinate Suspension (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name) Oral Suspension 400 mg (of erythromycin) per 5 mL E.E.S. Liquid (Abbott) Oral Suspension 400 mg (of erythromycin) per 5 mL Erythromycin Ethylsuccinate Suspension (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name) Oral Tablets, chewable 200 mg (of erythromycin) EryPed, scored (Abbott) Oral Tablets, film-coated 400 mg (of erythromycin) E.E.S. Filmtab (Abbott) Oral Tablets, film-coated 400 mg (of erythromycin) Erythromycin Ethylsuccinate Film-coated Tablets (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)
Erythromycin Stearate Preparations Route of Administration Dosage Form Strength Brand or Generic Name (Manufacturer) Oral Tablets, film-coated 250 mg (of erythromycin) Erythrocin Stearate Filmtab (Abbott) Oral Tablets, film-coated 250 mg (of erythromycin) Erythromycin Stearate Tablets (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name) Oral Tablets, film-coated 500 mg (of erythromycin) Erythrocin Stearate Filmtab (Abbott) Oral Tablets, film-coated 500 mg (of erythromycin) Erythromycin Stearate Tablets (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)
Erythromycin Preparations Route of Administration Dosage Form Strength Brand or Generic Name (Manufacturer) Ophthalmic Ointment 0.5% Erythromycin Ophthalmic Ointment (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name) Ophthalmic Ointment 0.5% Romycin (OCuSOFT)
Erythromycin Estolate Preparations Route of Administration Dosage Form Strength Brand or Generic Name (Manufacturer) Oral Capsules 250 mg (of erythromycin) Erythromycin Estolate Capsules (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name) Oral Suspension 125 mg (of erythromycin) per 5 mL Erythromycin Estolate Suspension (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name) Oral Suspension 250 mg (of erythromycin) per 5 mL Erythromycin Estolate Suspension (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)
Exposure Standards and Regulations
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including erythromycin, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including erythromycin ethyl succinate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Erythromycin ethyl succinate/
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including erythromycin lactobionate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Erythromycin lactobionate/
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including erythromycin stearate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Erythromycin stearate/
The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Erythromycin is included on this list.
The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Erythromycin phosphate is included on this list. /Erythromycin phosphate/
The Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Erythromycin thiocyanate is included on this list. /Erythromycin thiocyanate/
Erythromycin. (1) Dog - For the treatment of bacterial pneumonia, upper respiratory infections (tonsillitis, bronchitis, tracheitis, pharyngitis, pleurisy), endometritis and metritis, and bacterial wound infections caused by Staphylococcus spp., Streptococcus spp., and Corynebacterium spp., sensitive to erythromycin. ... (2) Cats - For the treatment of bacterial pneumonia, upper respiratory infections (rhinitis, bronchitis), secondary infections associated with panleukopenia, and bacterial wound infections caused by Staphylococcus spp. and Streptococcus spp., susceptible to erythromycin. ... (3) Cattle - For the treatment of bovine respiratory disease (shipping fever complex and bacterial pneumonia) associated with Pasteurella multocida susceptible to erythromycin.
Erythromycin. Treatment of mastitis due to Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, and Streptococcus uberis in lactating or dry cows.
Tolerances for residues of erythromycin in food are established as follows: (a) 0.1 part per million in uncooked edible tissues of beef cattle and swine. (b) Zero in milk. (c) 0.025 part per million in uncooked eggs. (d) 0.125 part per million (negligible residue) in uncooked edible tissues of chickens and turkeys.
New animal drugs for use in animal feeds. Erythromycin thiocyanate. /Erythromycin thiocyanate/ Erythromycin thiocyanate in grams per ton Indications for use Limitations 4.6 to 18.5 Chickens; growth promotion and feed efficiency 9.25 to 18.5 Turkeys; growth promotion and feed efficiency For turkeys not over 12 weeks of age 9.25 to 64.75 Swine; increase in weight gain, improved feed efficiency in starter pigs (9.25 to 64.75) and grower-finishing pigs (9.25) Starter ration for animals up to 35 lb body weight 18.5 Laying chickens; aids in increasing egg production 92.5 1. Chickens; as an aid in the prevention of chronic respiratory disease during periods of stress Feed for 2 day before stress and 3 to 6 day after stress; withdraw 24 hours before slaughter 2. Chickens; as an aid in the prevention of infectious coryza Feed for 7 to 14 days; withdraw 24 hours before slaughter 3. Turkeys; as an aid in the prevention of chronic respiratory disease during periods of stress Feed for 2 days before stress and 3 to 6 days after stress 185 1. Chickens; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease Feed for 5 to 8 days; do not use in birds producing eggs for food purposes; withdraw 48 hours before slaughter 2. Turkeys; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease Feed for 5 to 8 days; do not use in birds producing eggs for food purposes
Erythromycin phosphate ... (1) Broiler and replacement chickens - As an aid in the control of chronic respiratory disease due to Mycoplasma gallisepticum susceptible to erythromycin. ... (2) Replacement chickens and chicken breeders - As an aid in the control of infectious coryza due to Hemophilus gallinarum susceptible to erythromycin. ... (3) Growing turkeys - As an aid in the control of blue comb (nonspecific infectious enteritis) caused by organisms susceptible to erythromycin. /Erythromycin phosphate/
Other Preventative Measures
Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be sued to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials.
As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mist, and/or vapors associated with this material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly.
For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.
Maintain eyewash facilities in the work area.
SRP: The scientific literature for the use of contact lenses by industrial workers is inconsistent. The benefits or detrimental effects of wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance, characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any event, the usual eye protection equipment should be worn even when contact lenses are in place.
SRP: Contaminated protective clothing should be segregated in a manner that results in no direct personal contact by personnel who handle, dispose of, or clean the clothing. Quality assurance procedures to confirm the efficacy of the cleaning procedures should be implemented prior to the decontaminated protective clothing being returned for reuse by the workers. Contaminated clothing (including shoes/socks) should not be taken home at end of shift, but should remain at employee's place of work for cleaning.
Protective Equipment and Clothing
For handling of laboratory scale quantities, a cloth lab coat is recommended. Where significant quantities are handled, work clothing may be necessary to prevent take-home contamination.
Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (eg, bearing the ANSI Z87 OR CSA stamp) is preferred.
Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place.
Specification

? Erythromycin (CAS NO.114-07-8), its Synonyms are (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione ; Abboticin ; Abomacetin ; Acneryne ; Acnesol ; Endoeritrin ; Erecin ; Erimycin-T . It is white to off white crystalline powder.

Octanol/Water Partition Coefficient
log Kow = 3.06 [McFarland JW et al; J Med Chem 40: 1340-6 (1997)] PubMed Abstract
Report

EPA Genetic Toxicology Program.

Disposal Methods
SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.
MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Eye irritation, Category 2

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word

Warning

Hazard statement(s)

H319 Causes serious eye irritation

Precautionary statement(s)
Prevention

P264 Wash ... thoroughly after handling.

P280 Wear protective gloves/protective clothing/eye protection/face protection.

Response

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P337+P313 If eye irritation persists: Get medical advice/attention.

Storage

none

Disposal

none

2.3 Other hazards which do not result in classification

none

Precursor and Product
Computational chemical data
  • Molecular Weight:733.937g/mol
  • Molecular Formula:C37H67NO13
  • Compound Is Canonicalized:True
  • XLogP3-AA:2.7
  • Exact Mass:733.461
  • Monoisotopic Mass:733.461
  • Complexity:1180
  • Rotatable Bond Count:7
  • Hydrogen Bond Donor Count:5
  • Hydrogen Bond Acceptor Count:14
  • Topological Polar Surface Area:194A^2
  • Heavy Atom Count:51
  • Defined Atom Stereocenter Count:18
  • Undefined Atom Stereocenter Count:0
  • Defined Bond Stereocenter Count:0
  • Undefined Bond Stereocenter Count:0
  • Isotope Atom Count:0
  • Covalently-Bonded Unit Count:1
  • CACTVS Substructure Key Fingerprint: AAADcfB+PAAAAAAAAAAAAAAAAAAAAAAAAAAkSAAAAAAAAAAAAAAAHgAACAAADXzxgAcCCAMABgAI AICQCAAAAAAAAAAAAAEIAAATEBYAgAAmQAAHIAAXAAHK7PzOAAAAAAAAAAAAAAAAAAAAAAAAAAAA AA==
Recommended Suppliers
  • Tel:86-311-66561638
  • Fax:86-311-66561638
  • Tel:86-0-17166540883
  • Fax:86-0-17166540883
  • Tel:0086-27-59207850
  • Fax:0086-27-59524646
  • Tel:86-571-88938639
  • Fax:86-571-88938652
  • Tel:86-571-85829152
  • Fax:86-571-85829153
  • Tel:+86-0592-5567629
  • Fax:+86-0592-5567629
  • Tel:86-27-13407111142
  • Fax:86-27-13407111142
  • Tel:86-25-83697070
  • Fax:86-25-83453275
  • Tel:86-571-87396430
  • Fax:86-571-87396431
Recommended Suppliers
  • Tel:86-311-66561638
  • Fax:86-311-66561638
  • Tel:86-0-17166540883
  • Fax:86-0-17166540883
  • Tel:0086-27-59207850
  • Fax:0086-27-59524646
  • Tel:86-571-88938639
  • Fax:86-571-88938652
  • Tel:86-571-85829152
  • Fax:86-571-85829153
  • Tel:+86-0592-5567629
  • Fax:+86-0592-5567629
  • Tel:86-27-13407111142
  • Fax:86-27-13407111142
  • Tel:86-25-83697070
  • Fax:86-25-83453275
  • Tel:86-571-87396430
  • Fax:86-571-87396431
 
<